Table 2.
Post-donation outcomes of living kidney donors with HIV.
| Donor 1 | Donor 2 | Donor 3 | |
|---|---|---|---|
| Post-donation follow-up outcomes, regardless of HIV status | |||
| Last follow-up time point | Year 4 | Year 3 | Year 2 |
| Blood pressure | 112/77 mmHg | 145/84 mmHg | 134/80 mmHg |
| SCr, year 1 | 0.99 mg/dL | 1.7 mg/dL | 1.93 mg/dL |
| Year 2 | 0.98 mg/dL | 1.6 mg/dL | 1.95 mg/dL |
| Year 3 | 0.90 mg/dL | 1.5 mg/dL | NA |
| Year 4 | 0.98 mg/dL | NA | NA |
| eGFR∗, year 1 | 74 (76) mL/min/1.73 m2 | 48 (51) mL/min/1.73 m2 | 40 (41) mL/min/1.73 m2 |
| Year 2 | 74 (76) mL/min/1.73 m2 | 48 (51) mL/min/1.73 m2 | 39 (41) mL/min/1.73 m2 |
| Year 3 | 82 (84) mL/min/1.73 m2 | 52 (55) mL/min/1.73 m2 | NA |
| Year 4 | 73 (76) mL/min/1.73 m2 | NA | NA |
| Urine ACR, year 1 | <4 mg/g | ND | 41 mg/g |
| Year 2 | 3 mg/g | 26 mg/g | 64 mg/g |
| Year 3 | <2 mg/g | 39 mg/g | NA |
| Year 4 | <2 mg/g | NA | NA |
| Calcium, year 1 | 9.7 mg/dL | 9.6 mg/dL | 9.6 mg/dL |
| Year 2 | 11.3 mg/dL | 9.6 mg/dL | 10.2 mg/dL |
| Year 3 | 9.5 mg/dL | 8.7 mg/dL | NA |
| Year 4 | 9.6 mg/dL | NA | NA |
| Phosphorus, year 1 | 3.9 mg/dL | 3.4 mg/dL | ND |
| Year 2 | 3.0 mg/dL | 4.4 mg/dL | 2.5 mg/dL |
| Year 3 | 2.3 mg/dL | 3.1 mg/dL | NA |
| Year 4 | 2.2 mg/dL | NA | NA |
| PTH, year 1 | 17 pg/mL | ND | ND |
| Year 2 | 58 pg/mL | ND | ND |
| Year 3 | 74 pg/mL | 44 pg/mL | NA |
| Year 4 | 67 pg/mL | NA | NA |
| Post-donation follow up outcomes, specific to research protocol for donors with HIV | |||
| Cystatin C+, month 6 | 0.94 mg/L (87 mL/min/1.73 m2) | ND | ND |
| Year 1 | ND | ND | ND |
| Year 2 | 0.91 mg/L (90 mL/min/1.73 m2) | ND | ND |
| Year 3 | 0.90 mg/L (90 mL/min/1.73 m2) | ND | NA |
| Year 4 | 1.0 mg/L (79 mL/min 1.73 m2) | ND | NA |
| mGFR, iohexol, month 6 | 83 mL/min/1.73 m2 | ND | ND |
| Year 1 | ND | ND | ND |
| Year 2 | 78 mL/min/1.73 m2 | ND | ND |
| Year 3 | 86 mL/min/1.73 m2 | ND | NA |
| Year 4 | 84 mL/min/1.73 m2 | NA | NA |
| HIV viral load, year 1 | <20 c/mL | <20 c/mL | <20 c/mL |
| Year 2 | <20 c/mL | <20 c/mL | <20 c/mL |
| Year 3 | <20 c/mL | <20 c/mL | NA |
| Year 4 | <20 c/mL | NA | NA |
| Absolute CD4, year 1 | 473 cells/μL | 511 cells/μL | 984 cells/μL |
| Year 2 | 643 cells/μL | 574 cells/μL | ND |
| Year 3 | 599 cells/μL | 398 cells/μL | NA |
| Year 4 | 675 cells/μL | NA | NA |
| ART post-donation | RPV TAF FTC | ABC 3TC DTG | DOR 3TC DTG |
| Changes to ART due to renal function | No | No | No |
NA, not applicable; SCr, serum creatinine; eGFR∗, estimated glomerular filtration rate with Chronic Kidney Disease Epidemiology (CKD-EPI) 2009 equation and CKD-EPI 2021 equation estimate following in parentheses; ACR, albumin/creatinine ratio; PTH, parathyroid hormone; Cystatin C+, estimated glomerular filtration rate with CKD-EPI Cystatin C 2012 equation following in parentheses; ND, no data; ART, antiretroviral therapy; RPV, rilpivirine; TAF, tenofovir alafenamide; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; DTG, dolutegravir; DOR, doravirine.